On the fly News and insights, exclusive to thefly.com

2021-05-13 09:53:27 ATRA Atara Biotherapeutics $14.97 / +1.13 (+8.16%) , LOW Lowe's $199.89 / +4.36 (+2.23%) … 09:53 05/13/21 05/13 09:53 05/13/21 09:53	Fly Intel: Top five analyst upgrades Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Atara Biotherapeutics (ATRA) upgraded to Overweight from Neutral at JPMorgan with analyst Anupam Rama saying the most recent U.S. physician survey showed "clear enthusiasm" for ATA188 despite the early stage of the Phase 1 results in progressive multiple sclerosis. 2. Lowe's (LOW) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Nagel saying the upgrade is "largely tactical in nature" and based on the prospects for a continued flow of funds into more cyclically focused equites as well as Lowe's "now historically discounted valuation" versus that of Home Depot (HD). 3. BJ's Wholesale (BJ) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Horvers making a risk/reward call as he sees potential upside to the consensus Q1 comp estimate of down 9%. 4. Pioneer Natural (PXD) upgraded to Overweight from Sector Weight at KeyBanc with analyst Leo Mariani expecting the company's 2021 oil production to come in 1.4% above the high end of its guidance. 5. Ventas (VTR) upgraded to Outperform from Neutral at Baird and upgraded to Overweight from Underweight at KeyBanc. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. ATRA Atara Biotherapeutics $14.97 / +1.13 (+8.16%) LOW Lowe's $199.89 / +4.36 (+2.23%) BJ BJ's Wholesale $45.75 / +2.28 (+5.24%) PXD Pioneer Natural $155.33 / -0.75 (-0.48%) VTR Ventas $53.17 / +0.98 (+1.88%)	19 May 20 May 25 May 27 May 28 May 08 Jun 08 Jun 17 Jun 27 May 09 Dec 11 May

2021-05-13 09:53:27

ATRA

Atara Biotherapeutics

$14.97 / +1.13 (+8.16%)

, LOW

Lowe's

$199.89 / +4.36 (+2.23%)

… 09:53

05/13/21

05/13

09:53

05/13/21

09:53

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Atara Biotherapeutics (ATRA) upgraded to Overweight from Neutral at JPMorgan with analyst Anupam Rama saying the most recent U.S. physician survey showed "clear enthusiasm" for ATA188 despite the early stage of the Phase 1 results in progressive multiple sclerosis. 2. Lowe's (LOW) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Nagel saying the upgrade is "largely tactical in nature" and based on the prospects for a continued flow of funds into more cyclically focused equites as well as Lowe's "now historically discounted valuation" versus that of Home Depot (HD). 3. BJ's Wholesale (BJ) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Horvers making a risk/reward call as he sees potential upside to the consensus Q1 comp estimate of down 9%. 4. Pioneer Natural (PXD) upgraded to Overweight from Sector Weight at KeyBanc with analyst Leo Mariani expecting the company's 2021 oil production to come in 1.4% above the high end of its guidance. 5. Ventas (VTR) upgraded to Outperform from Neutral at Baird and upgraded to Overweight from Underweight at KeyBanc. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ATRA

Atara Biotherapeutics